AstraZeneca: Calquence-based Regimens Approved In EU For Patients With Chronic Lymphocytic Leukaemia

(RTTNews) - AstraZeneca said a fixed-duration regimen of Calquence in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia. The approval by th https://www.nasdaq.com/articles/astrazeneca-calquence-based-regimens-approved-eu-patients-chronic-lymphocytic-leukaemia